Ridley Life Science Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 8.28 Cr
as on 23-10-2024
- Company Age 20 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 24.44 Cr
as on 23-10-2024
- Satisfied Charges ₹ 2.98 Cr
as on 23-10-2024
- Revenue -45.57%
(FY 2023)
- Profit -154.60%
(FY 2023)
- Ebitda -16.00%
(FY 2023)
- Net Worth -1.72%
(FY 2023)
- Total Assets -37.71%
(FY 2023)
About Ridley Life Science
The Corporate was formerly known as Terex Pharmaceuticals Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 8.28 Cr.
The company currently has active open charges totaling ₹24.44 Cr. The company has closed loans amounting to ₹2.98 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Bansal, Ram Gautam, and Rakesh Bansal serve as directors at the Company.
- CIN/LLPIN
U24232DL2004PTC129295
- Company No.
129295
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Sep 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ridley Life Science?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Bansal  | Director | 21-Sep-2004 | Current |
| Ram Gautam | Director | 15-Nov-2019 | Current |
| Rakesh Bansal | Director | 21-Sep-2004 | Current |
Financial Performance of Ridley Life Science.
Ridley Life Science Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 45.57% decrease. The company also saw a substantial fall in profitability, with a 154.6% decrease in profit. The company's net worth dipped by a decrease of 1.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ridley Life Science?
In 2023, Ridley Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 28 Aug 2020 | ₹16.94 Cr | Open |
Bank Of Baroda Creation Date: 15 Jun 2012 | ₹7.50 Cr | Open |
Others Creation Date: 19 May 2020 | ₹5.50 M | Satisfied |
How Many Employees Work at Ridley Life Science?
Ridley Life Science has a workforce of 30 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ridley Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ridley Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
